Skip to main content

Advertisement

Table 1 Secondary outcomes

From: No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis

  Success group Failure group
Primoinfections [n] 33 16
Age at diagnosis [years] 9.3 9.1
  p value 0.842 (T test)
Symptoms at diagnosis [%] 81.8 87.5
  p value 0.118 (McNemar)
 Cough [%] 66.7 87.5
 Upper respiratory tract infect. [%] 39.4 25.0
 Dyspnea [%] 3.0 12.5
 Fever [%] 3.0 12.5
Diagnostic methods [%]
 Sputum samples 69.7 75.0
 Oropharyngeal swab 30.3 25.0
  p value 0.831 (McNemar)
  Diagn. Follow-up Diagn. Follow-up
FEV1 [%]
 Mean 107.7 107.8 104.7 99.1
 Median 103 103 104 99.5
 p value 0.772 (Wilcoxon) 0.312 (T test)
BMI [kg/m2]
 Mean 16.3 16.6 16.9 17.1
 Median 15.8 16.0 16.6 16.2
 p value 0.024 (Wilcoxon) 0.083 (Wilcoxon)
  1. Among symptomatic patients, distribution of most frequent symptoms. A patient may have more than one symptom (in italics)